X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TRP-8803 (Psilocin) provides a proprietary formulation of psilocin administered by IV infusion. It is being evaluated for the treatment of binge eating disorder, fibromyalgia.
Lead Product(s): Psilocin
Therapeutic Area: Psychiatry/Psychology Product Name: TRP-8803
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
TRP-8802 (psilocybin) is a 5-HT2A receptor agonist - oral formulation which is being evaluated in phase 2 clinical studies for the treatment of fibromyalgia.
Lead Product(s): Psilocybine
Therapeutic Area: Musculoskeletal Product Name: TRP-8802
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
The proceeds will be used to advance Tryp's research and development programs, including TRP-8802 (psilocybin) in patients with Binge Eating Disorder.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: TRP-8802
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alto Capital
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 20, 2023
Details:
The proceeds will be used to advance Tryp's research and development programs, including TRP-8802 (psilocybin) in patients with Binge Eating Disorder.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: TRP-8802
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alto Capital
Deal Size: $1.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 02, 2023
Details:
The proceeds of the Private placement will be used to advance Tryp's research and development program TRYP-0082 (psilocybin) and for general working capital purposes.
Lead Product(s): Psilocin
Therapeutic Area: Psychiatry/Psychology Product Name: TRYP-0082
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alto Capital Limited
Deal Size: $0.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 11, 2023
Details:
TRP-8802 (Oral psilocybin) in patients withIrritable Bowel Syndrome, represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with Irritable Bowel Syndrome.
Lead Product(s): Psilocybine
Therapeutic Area: Gastroenterology Product Name: TRP-8802
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Massachusetts General Hospital
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
TRP-8802 (Oral psilocybin) in patients with Irritable Bowel Syndrome, represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with IBS.
Lead Product(s): Psilocybine
Therapeutic Area: Gastroenterology Product Name: TRP-8802
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
The proceeds of the Private Placement will be used to advance Tryp's research and development programs including, TRYP-0082 (psilocybin), being development in the treatment of Binge Eating Disorder.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: TRYP-0082
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Westar Capital Limited
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 12, 2023
Details:
The planned study will evaluate the effect of TRP-8803, psilocybin-assisted psychotherapy in patients with treatment-resistant IBS who experience chronic abdominal pain and other debilitating gastrointestinal symptoms.
Lead Product(s): Psilocin
Therapeutic Area: Gastroenterology Product Name: TRP-8803
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
TRP-8802 (Oral psilocybin) in patients with binge eating disorder (“BED”), represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with BED.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: TRP-8802
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
